HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Esapent

Also Known As:
Esprit
Networked: 71 relevant articles (4 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. ESPRIT Study Group: 5 articles (04/2011 - 01/2006)
2. Ritchie, Karen: 4 articles (11/2014 - 05/2009)
3. Halkes, P H A: 4 articles (04/2009 - 05/2006)
4. Kappelle, L J: 4 articles (04/2009 - 05/2006)
5. Algra, A: 4 articles (04/2009 - 05/2006)
6. Koudstaal, P J: 4 articles (04/2009 - 05/2006)
7. van Gijn, J: 4 articles (04/2009 - 05/2006)
8. Tcheng, James E: 4 articles (11/2004 - 01/2002)
9. Artero, Sylvaine: 3 articles (11/2014 - 07/2010)
10. Kitt, Michael M: 3 articles (11/2004 - 01/2002)

Related Diseases

1. Stroke (Strokes)
2. Hemarthrosis
3. Myocardial Infarction
4. Ischemia
5. Hemorrhage
01/01/2004 - "The incidence of intracranial bleeding was 0.2% in ESPRIT (0.1% in the placebo group) and 0.7% in PURSUIT (0.8% in the placebo group). "
09/01/2011 - "In ESPRIT (patients with ischaemic stroke/TIA) for the primary outcome (first occurrence of death from all vascular causes, non-fatal stroke, non-fatal MI or major bleeding complication), the risk of event occurrence was statistically significantly lower in the MRD + ASA arm than in the ASA arm [hazard ratio (HR) 0.80; 95% CI 0.66 to 0.98], with no statistically significant difference in bleeding events between the two arms. "
01/01/2004 - "In the eptifibatide studies, the rates of major bleeding were 0.7% (0.5% in the control group) in ESPRIT and 2.1% (1.3% in the placebo group) in PURSUIT. "
02/23/2008 - "Two major trials, the 'Stroke prevention in reversible ischemia trial' (SPIRIT) and the 'European/Australasian stroke prevention in reversible ischaemia trial' (ESPRIT), showed that vitamin K antagonists were more effective than placebo in the prevention of ischaemic stroke, but the favourable effect was completely offset by a higher incidence of major bleeding (including intracerebral bleeding) in patients using vitamin K antagonists. "
11/01/2006 - "Pooled data from 3 studies (REPLACE-2 [second Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischaemia Trial], and EPISTENT [Evaluation of Platelet IIb/IIIa Inhibitor for Stenting]) were used as the source for the probabilities of myocardial infarction (MI), urgent revascularization (UR), major and minor bleeding (Thrombolysis in Myocardial Infarction study definitions), and death. "

Related Drugs and Biologics

1. Aspirin (Acetylsalicylic Acid)
2. Dipyridamole (Persantine)
3. eptifibatide (Integrilin)
4. clopidogrel (Plavix)
5. Interleukin-2 (IL2)
6. Platelet Aggregation Inhibitors (Antiplatelet Drugs)
7. Anticoagulants
8. estradiol valerate (Delestrogen)
9. Simvastatin (Zocor)
10. Vitamin K

Related Therapies and Procedures

1. Stents
2. Hormone Replacement Therapy (Therapy, Hormone Replacement)
3. Transplants (Transplant)
4. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5. Cochlear Implants (Cochlear Implant)